Novel Wearable Device for Heart Failure Management
Heart Failure
About this trial
This is an interventional screening trial for Heart Failure focused on measuring Novel Wearable Device, remote monitoring, Right heart catheterization
Eligibility Criteria
Inclusion Criteria: Diagnosis of HF ≥ 3 months Diagnosis of NYHA Class III HF Subjects with age ≥ 18 years At least 1 HF hospitalization within 12 months prior to enrollment Subjects with elevated ambulatory levels of BNP/NT-proBNP Exclusion Criteria: Subjects unable to cooperate to complete the trial. Subjects with severe arrhythmia. Subjects with cardiac shock. Subjects with acute myocardial infarction. Subjects with local skin infections and injuries in the jugular vein area Subjects with active uncontrolled infections Subjects with eGFR < 25 mL/min/1.73m2 Pregnant women, or women likely to undergo pregnancy Subjects with life expectancy less than 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Novel wearable device strategy group
Control group
Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps.
Patients receive a standard of care for heart failure without a wearable device.